Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
o" x3 E# A3 U- I% O: xNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
8 G$ W; K3 F& P& s+ Author Affiliations# ^) P- U/ Y8 i4 p
+ s9 \7 [# P/ X0 ?
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
7 U9 Y. a" x1 U$ y% q9 m- Y2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
" \* A0 r; F1 E3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 7 U c, [2 V9 i- m: Q0 r9 ^5 L
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ; n; B) }7 H1 |
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
' L7 _7 m, D$ g. H6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
1 h1 I- n6 ~( p- A7Kinki University School of Medicine, Osaka 589-8511, Japan 2 r5 \" ~8 E& I) }- b" H) G
8Izumi Municipal Hospital, Osaka 594-0071, Japan
) x1 i, T% {3 k* _) `3 ]+ m! P9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
0 O( H% H$ Y( C9 u8 D% L2 q% ?Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp $ I, Y- ^; q5 ~* F' \
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. ( Y. x# S8 b9 \2 e6 S! U
/ `& C3 U! R' g# |4 `
|